New Biomarker Test Allows Early Detection of Adverse Prognosis After Acute Kidney Injury

CINCINNATI – A new biomarker-based diagnostic test is more effective than the current best practice for early detection of adverse outcomes after acute kidney injury (AKI), which can be fatal for an estimated 50 percent of the critically ill patients who get the condition.

A multi-center study to be published April 26 in the Journal of the American College of Cardiology (JACC) reports that a kidney injury biomarker called "neutrophil gelatinase-associated lipocalin” (NGAL) in urine or blood detects early subclinical AKI and its adverse outcomes in critically ill patients.

These same patients did not have diagnostic increases in serum creatinine, which is considered the current gold standard for detecting AKI. Early NGAL testing may therefore allow earlier conventional medical interventions or introduction of novel therapies to improve the prognosis of AKI, the authors write.

Results of the retrospective study – which included pooled data from 2,322 critically ill adult and pediatric patients – also justify recommending a reassessment of what defines AKI, according to researchers from 13 international medical organizations collaborating on the study.

"This has enormous implications because AKI affects about 30 percent of all critically ill patients, in whom current therapeutic options are limited and unacceptably delayed.”

The critically ill patients whose data researchers analyzed primarily had Type 1 cardiorenal syndrome, a common condition in which heart dysfunction causes kidney injury. The researchers were surprised to learn that 40 percent of the patients showed unexpected early increases in urine or blood NGAL levels, but no increases in serum creatinine.

Even more unexpected was that those patients with early increases in NGAL concentration had a much greater risk of adverse medical outcomes than patients who tested negative for NGAL.

NGAL positive patients were 16 times more likely to need dialysis, three times more likely to die during hospitalization, and on average they spent three extra days in intensive care and eight extra days in the hospital.

"We concluded that these substantial numbers of patients might reasonably be classified as having sub-clinical AKI, even though they do not fulfill current creatinine-based criteria for AKI,” Devarajan said.

"Our findings dictate a need for complete reassessment of the very concept of and diagnosis of AKI. They also point to an urgent need for testing whether NGAL-based early diagnosis of AKI can lead to timelier deployment of therapies and improved outcomes.”

"Our findings suggest an important analogy between the troponin/creatine kinase relationship in acute myocardial infarction and the NGAL/creatinine relationship in AKI for the identification of previously undetected organ injury,” said Bellomo, director of intensive care research at Austin Hospital, and senior author of this study.

"Just as the increased diagnostic sensitivity of troponin has dramatically altered the definition, diagnosis, and management of acute myocardial infarction, similar concepts might apply to NGAL and AKI.”

The researchers now plan to pursue a prospective multi-center study to further verify the effectiveness of the NGAL test as a prognostic biomarker in a large population of patients in critical care settings.

Patents and intellectual property rights for the use of NGAL for earlier acute kidney injury diagnosis are jointly owned by Cincinnati Children’s and Columbia University in New York.

The technology has been exclusively licensed to industry (Abbott Diagnostics, Biosite, Inc.) for clinical development and commercialization.

Standardized clinical laboratory tests for detecting urine and blood NGAL are being used globally and currently under evaluation by the U.S. Food and Drug Administration for use in the United States.

Devarajan and Bellomo have acted as paid consultants to Abbott and Biosite, Inc. and Haase has received an honorarium for speaking for Abbott and Biosite.